Clinical Rheumatology

, Volume 34, Issue 9, pp 1563–1569 | Cite as

Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD)

  • Jorge Rojas-Serrano
  • Denisse Herrera-Bringas
  • Mayra Mejía
  • Hermes Rivero
  • Heidegger Mateos-Toledo
  • José E. Figueroa
Original Article
First Online:
Received:
Revised:
Accepted:

Abstract

The objectives of the present study were to compare the survival function of antisynthetase syndrome (ASS) Jo1-positive patients with ASS non-Jo1 patients, all with interstitial lung disease (ILD), and to evaluate other factors such as the extension of pulmonary disease and the time between the onset of symptoms and diagnosis and its association to survival in a cohort of ASS patients. Patients with ASS, all with ILD, were included. At the baseline, pulmonary function tests were realized and a high-resolution chest tomography was obtained; lung inflammation and fibrosis were measured with the Goh score and the Kazerooni index. The following autoantibodies were measured: Jo1, Ej, Oj, PL7, and PL12. Patients had to be positive for one of them in order to be included in the study. The survival function was estimated and compared with the log rank test, and the hazard ratio (HR) was estimated using Cox regression procedure. Forty-three patients were included, of which six patients died (14 %). Patients who died were different in comparison with survivors as regards the frequency of anti-Jo1 positivity: Survivors had anti-Jo1 autoantibodies more frequently (86 %) than patients who died (50 %). The univariate Cox regression analysis identified four variables associated with survival: Jo1 status, arthritis, extent of ground glass, and consolidation (inflammation) in high-resolution computed tomography (HRCT) and baseline forced vital capacity. The serological status of patients (Jo1-positive vs non-Jo1), the extent of lung inflammation in the HRCT scan, a low forced vital capacity, and arthritis are associated with survival in ASS patients.

Keywords

Antisynthetase antibodies Antisynthetase syndrome Interstitial lung disease Jo1 autoantibody 
This is a preview of subscription content, log in to check access.

Notes

Disclosures

None.

Founding source

There is no founding source for this study.

References

  1. 1.
    Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Med Chem Commun 70(6):360–374Google Scholar
  2. 2.
    Mahler M, Miller FW, Fritzler MJ (2014) Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev 13(4-5):367–371PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Marie I (2012) Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Reports 14(3):275–285CrossRefGoogle Scholar
  4. 4.
    Marie I, Josse S, Hatron PY, Dominique S, Hachulla E, Janvresse A, Cherin P, Mouthon L, Vittecoq O, Menard JF et al (2013) Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res (Hoboken) 65(5):800–808CrossRefGoogle Scholar
  5. 5.
    Marie I, Josse S, Decaux O, Dominique S, Diot E, Landron C, Roblot P, Jouneau S, Hatron PY, Tiev KP et al (2012) Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 11(10):739–745CrossRefPubMedGoogle Scholar
  6. 6.
    Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, Oddis CV (2014) Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 73(1):227–232CrossRefPubMedGoogle Scholar
  7. 7.
    Hervier B, Devilliers H, Stanciu R, Meyer A, Uzunhan Y, Masseau A, Dubucquoi S, Hatron PY, Musset L, Wallaert B et al (2012) Hierarchical cluster and survival analyses of antisynthetase syndrome: Phenotype and outcome are correlated with anti-tRNAsynthetase antibody specificity. Autoimmun Rev 12(2):210–217CrossRefPubMedGoogle Scholar
  8. 8.
    Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344–347CrossRefPubMedGoogle Scholar
  9. 9.
    Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292(8):403–407CrossRefPubMedGoogle Scholar
  10. 10.
    Fischer A, Du BR (2012) Interstitial lung disease in connective tissue disorders. Lancet 380(9842):689–698CrossRefPubMedGoogle Scholar
  11. 11.
    Ghirardello A, Rampudda M, Ekholm L, Bassi N, Tarricone E, Zampieri S, Zen M, Vattemi GA, Lundberg IE, Doria A (2010) Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford) 49(12):2370–2374CrossRefGoogle Scholar
  12. 12.
    Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, Cascade PN, Whyte RI, Lynch JP III, Toews G (1997) Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR AmJRoentgenol 169(4):977–983CrossRefGoogle Scholar
  13. 13.
    Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, Corte TJ, Sander CR, Ratoff J, Devaraj A et al (2008) Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Critical Xare Med 177(11):1248–1254CrossRefGoogle Scholar
  14. 14.
    Hervier B, Devilliers H, Benveniste O (2013) Patients with non-Jo-1 anti-RNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 72(7), e18CrossRefPubMedGoogle Scholar
  15. 15.
    Friedman AW, Targoff IN, Arnett FC (1996) Interstitial lung disease with autoantibodies against aminoacyl-tRNAsynthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 26(1):459–467CrossRefPubMedGoogle Scholar
  16. 16.
    Hamaguchi Y, Fujimoto M, Matsushita T, Kaji K, Komura K, Hasegawa M, Kodera M, Muroi E, Fujikawa K, Seishima M et al (2013) Common and distinct clinical features in adult patients with anti-aminoacyl-tRNAsynthetase antibodies: heterogeneity within the syndrome. PLoS One 8(4), e60442PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Hervier B, Benveniste O (2013) Clinical heterogeneity and outcomes of antisynthetase syndrome. Curr Rheumatol Rep 15(8):349CrossRefPubMedGoogle Scholar
  18. 18.
    Hervier B, Lambert M, Hachulla E, Musset L, Benveniste O, Piette JC, Amoura Z, Costedoat-Chalumeau N (2011) Anti-synthetase syndrome positive for anti-isoleucyl-tRNAsynthetase antibodies: an unusual case overlapping with systemic sclerosis and Sjogren's syndrome. Rheumatology (Oxford) 50(6):1175–1176CrossRefGoogle Scholar
  19. 19.
    Hervier B, Uzunhan Y, Hachulla E, Benveniste O, Nunes H, Delaval P, Musset L, Dubucquoi S, Wallaert B, Hamidou M (2011) Antisynthetase syndrome positive for anti-threonyl-tRNAsynthetase (anti-PL7) antibodies. EurRespir J 37(3):714–717CrossRefGoogle Scholar
  20. 20.
    Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF (2011) Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 63(11):3439–3447CrossRefPubMedGoogle Scholar
  21. 21.
    Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF, Levesque H, Jouen F (2012) Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum 41(6):890–899CrossRefPubMedGoogle Scholar
  22. 22.
    Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Aihara K, Ikezoe K, Watanabe K, Taguchi Y, Hatta K et al (2013) The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med 107(5):745–752CrossRefPubMedGoogle Scholar
  23. 23.
    Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN, Dawson J, Sathi N, Ahmad Y, Koduri G et al (2014) Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study. Rheumatology 53(9):1676–1682CrossRefPubMedGoogle Scholar
  24. 24.
    Perez-Dorame R, Mejia M, Mateos-Toledo H, Rojas-Serrano J (2014) Rheumatoid arthritis-associated interstitial lung disease: Lung inflammation evaluated with high resolution computed tomography scan is correlated to rheumatoid arthritis disease activity. Reumatologiaclinica Google Scholar
  25. 25.
    Rojas-Serrano J, Gonzalez-Velasquez E, Mejia M, Sanchez-Rodriguez A, Carrillo G (2012) Interstitial lung disease related to rheumatoid arthritis: evolution after treatment. ReumatolClin 8(2):68–71Google Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2015

Authors and Affiliations

  • Jorge Rojas-Serrano
    • 1
    • 2
  • Denisse Herrera-Bringas
    • 1
  • Mayra Mejía
    • 1
  • Hermes Rivero
    • 3
  • Heidegger Mateos-Toledo
    • 1
  • José E. Figueroa
    • 4
  1. 1.Interstitial Lung Disease and Rheumatology UnitsInstituto Nacional de Enfermedades Respiratorias, Ismael Cosío VillegasMéxicoMéxico
  2. 2.Programa de Maestría y Doctorado en Ciencias Médicas, Facultad de MedicinaUniversidad Nacional Autónoma de MéxicoMexicoMexico
  3. 3.Hospital Universitario de CaracasUniversidad Central de VenezuelaCaracasVenezuela
  4. 4.Clinical LaboratoryInstituto Nacional de Enfermedades Respiratorias, Ismael Cosío VillegasMexicoMexico

Personalised recommendations